Published in Drug Week, June 10th, 2005
Investigators in Sweden evaluated the utility of "as-needed treatment with formoterol compared with the short-acting alternative terbutaline."
"Two double-blind, 12-month, parallel-group, non-inferiority trials comparing as-needed use of formoterol (Oxis) 4.5 microg and terbutaline (Bricanyl) 0.5 mg via dry-powder inhaler (Turbuhaler), one in 675 patients with intermittent and one in 455 patients with mild persistent asthma," were conducted by A. Chuchalin and coauthors at AstraZeneca R&D Lund.
Participants ranged from "6-87 years of age," the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.